Comparative of radiation technology of IMRT, VMAT and HT applied to lung cancer stereotactic body radiotherapy

doi:10.3760/cma.j.issn.1673-422X.2017.04.012

Abstract

Abstract: The radiation techniques for lung cancer stereotactic body radiotherapy (SBRT) include intensity modulated radiation therapy (IMRT), volumetric modulated arc therapy （VMAT） and helical tomotherapy (HT). Concerning the target conformity and dosimetric homogeneity index, HT and VMAT technologies are superior to IMRT. On the contrary, HT and VMAT technology can increase low dose area irradiated of lung. Comparing to other two technologies, VMAT can obviously shorten the treatment time. At present, there is no consensus how to choose individually optimized radiotherapy technology for different location and stages lung tumors.

Key words: Lung tumors, Radiotherapy, Stereotactic body radiotherapy

Yuan Daozu, Lyu Jiahua, Li Qi, Li Tao. Comparative of radiation technology of IMRT, VMAT and HT applied to lung cancer stereotactic body radiotherapy[J]. Journal of International Oncology, 2017, 44(4): 287-289.

References

［1］ Chen W, Zheng R, Peter PD, et al. Cancer statistics in China, 2015［J］. CA Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338. ［2］ Chang JY, Liu H, Balter P, et al. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage Ⅰ non-small cell lung cancer［J］. Radiat Oncol, 2012, 7: 152. DOI: 10.1186/1748-717X-7-152. ［3］ Taremi M, Hope A, Dahele M, et al. Stereotactic body radiotherapy for medically inoperable lung cancer: prospective, single-center study of 108 consecutive patients［J］. Int J Radiat Oncol Biol Phys, 2012, 82(2): 967-973. DOI: 10.1016/j.ijrobp.2010.12.039. ［4］ Verstegen NE, Oosterhuis JW, Palma DA, et al. Stage Ⅰ-Ⅱ nonsmallcell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis［J］. Ann Oncol, 2013, 24(6): 1543-1548. DOI: 10.1093/annonc/mdt026. ［5］ Nuyttens JJ, van der Voort van Zyp NC, Praag J, et al. Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors［J］. Radiother Oncol, 2012, 102(3): 383-387. DOI: 10.1016/j.radonc.2011.12.023. ［6］ Rowe BP, Boffa DJ, Wilson LD, et al. Stereotactic body radiotherapy for central lung tumors［J］. J Thorac Oncol, 2012, 7(9): 1394-1399. DOI: 10.1097/JTO.0b013e3182614bf3. ［7］ Casamassima F, Livi L, Masciullo S, et al. Stereotactic radiotherapy for adrenal gland metastases: university of Florence experience［J］. Int J Radiat Oncol Biol Phys, 2012, 82(2): 919-923. DOI: 10.1016/j.ijrobp.2010.11.060. ［8］ Barriger RB, Forquer JA, Brabham JG, et al. A dosevolume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy［J］. Int J Radiat Oncol Biol Phys, 2012, 82(1): 457-462. DOI: 10.1016/j.ijrobp.2010.08.056. ［9］ Bongers EM, Botticella A, Palma DA, et al. Predictive parameters of symptomatic radiation pneumonitis following stereotactic or hypofractionated radiotherapy delivered using volumetric modulated arcs［J］. Radiother Oncol, 2013, 109(1): 95-99. DOI: 10.1016/j.radonc.2013.10.011. ［10］ Palma DA, Senan S, Tsujino K, et al. Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data metaanalysis［J］. Int J Radiat Oncol Biol Phys, 2013, 85(2): 444-450. DOI: 10.1016/j.ijrobp.2012.04.043. ［11］ Jiang X, Li T, Liu Y, et al. Planning analysis for locally advanced lung cancer: dosimetric and efficiency comparisons between intensity modulated radiotherapy (IMRT), single-arc/partial-arc volumetric modulated arc therapy (SA/PA-VMAT)［J］. Radiat Oncol, 2011, 6: 140-146. DOI: 10.1186/1748-717X-6-140. ［12］ McGrath SD, Mathuszak MM, Yan D, et al. Volumetric modulated arc therapy for delivery of hypofractionated stereotactic lung radiotherapy: a dosimetric and treatment efficiency analysis［J］. Radiother Oncol, 2010, 95(2): 153-157. DOI: 10.1016/j.radonc.2009.12.039. ［13］ Holt A, van VlietVroegindeweij C, Mans A, et al. Volumetric-modulated arc therapy for stereotactic body radiotherapy of lung tumors: a comparison with intensitymodulated radiotherapy techniques［J］. Int J Radiat Oncol Biol Phys, 2011, 81(5): 1560-1567. DOI: 10.1016/j.ijrobp.2010.09.014. ［14］ Rossi MM, Peulen HM, Belderbos JS, et al. Intrafraction motion in stereotactic body radiation therapy for non-small cell lung cancer: intensity modulated radiation therapy versus volumetric modulated arc therapy［J］. Int J Radiat Oncol Biol Phys, 2016, 95(2): 835-843. DOI: 10.1016/j.ijrobp.2016.01.060. ［15］ Ding L, Lo YC, Kadish S, et al. Volume modulated arc therapy (VMAT) for pulmonary stereotactic body radiotherapy (SBRT) in patients with lesions in close approximation to the chest wall［J］. Front Oncol, 2013, 3: 12. DOI: 10.3389/fonc.2013.00012. ［16］ Ong CL, Verbakel WF, Cuijpers JP, et al. Stereotactic radiotherapy for peripheral lung tumors: a comparison of volumetric modulated arc therapy with 3 other delivery techniques［J］. Radiother Oncol, 2010, 97(3): 437-442. DOI: 10.1016/j.radonc.2010.09.027. ［17］ Kannarunimit D, Descovich M, Garcia A, et al. Analysis of dose distribution and risk of pneumonitis in stereotactic body radiation therapy for centrally located lung tumors: a comparison of robotic radiosurgery, helical tomotherapy and volumetric modulated arc therapy［J］. Technol Cancer Res Treat, 2015, 14(1): 4960. DOI: 10.7785/tcrt.2012.500394. ［18］ Chi A, Ma P, Fu G, et al. Critical structure sparing in stereotactic ablative radiotherapy for central lung lesions: helical tomotherapy vs. volumetric modulated arc therapy［J］. PLoS One, 2013, 8(4): e59729. DOI: 10.1371/journal.pone.0059729. ［19］ Chen A, Lee N, Yang C, et al. Comparison of intensity-modulated radiotherapy using helical tomotherapy and segmental multileaf collimator-based techniques for nasopharyngeal carcinoma: dosimetric analysis incorporating quality assurance guidelines from RTOG 0225［J］. Technol Cancer Res Treat, 2010, 9(3): 291-298. ［20］ Meng LL, Feng LC, Wang YL, et al. Dosimetric comparison between helical tomotherapy and intensity-modulated radiation therapy plans for nonsmall cell lung cancer［J］. Chin Med J (Engl), 2011, 124(11): 1667-1671. ［21］ Kinhikar RA, Ghadi YG, Sahoo P, et al. Dosimetric comparison of three-dimensional conformal radiotherapy, intensity modulated radiotherapy, and helical tomotherapy for lung stereotactic body radiotherapy［J］. J Med Phys, 2015, 40(4): 190-197. DOI: 10.4103/0971-6203.170792. ［22］ Rao M, Yang W, Chen F, et al. Comparison of Elekta VMAT with helical tomotherapy and fixed field IMRT: plan quality, delivery efficiency and accuracy［J］. Med Phys, 2010, 37(3): 1350-1359. ［23］ Xhaferllari I, El-Sherif O, Gaede S. Comprehensive dosimetric planning comparison for early-stage, non-small cell lung cancer with SABR: fixed-beam IMRT versus VMAT versus Tomotherapy［J］. J Appl Clin Med Phys, 2016, 17(5): 6291. ［24］ Weyh A, Konski A, Nalichowski A, et al. Lung SBRT: dosimetric and delivery comparison of RapidArc, Tomotherapy, and IMR［J］. J Appl Clin Med Phys, 2013, 14(4): 4065. DOI: 10.1120/jacmp.v14i4.4065.

[1]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[4]	Qian Xiaotao, Shi Ziyi, Hu Ge. A real-world clinical study of immunocheckpoint inhibitor maintenance therapy after radical radiotherapy and chemotherapy in stage Ⅲ-ⅣA esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2024, 51(3): 151-156.
[5]	Li Shuyue, Ma Chenying, Zhou Juying, Xu Xiaoting, Qin Songbing. Progress of radiotherapy in oligometastatic non-small cell lung cancer [J]. Journal of International Oncology, 2024, 51(3): 170-174.
[6]	Gao Xinyu, Li Zhenjiang, Sun Hongfu, Han Dan, Zhao Qian, Liu Chengxin, Huang Wei. Clinical application of MR-guided radiotherapy based on MR-linac in esophageal cancer patients [J]. Journal of International Oncology, 2024, 51(1): 37-42.
[7]	Cui Tenglu, Lyu lu, Sun Pengfei. Application of radiotherapy combined with immunotherapy in the treatment of head and neck squamous cell carcinoma [J]. Journal of International Oncology, 2023, 50(9): 548-552.
[8]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[9]	Lyu Lu, Sun Pengfei. Gut flora and cervical cancer [J]. Journal of International Oncology, 2023, 50(6): 373-376.
[10]	Radiation Oncology Treatment Physician Branch, Chinese Medical Doctor Association, Radiation Oncology Therapy Branch, Chinese Medical Association, Chinese Association of Radiation Therapy, China Anti-Cancer Association. Chinese experts' consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy （2023 version） [J]. Journal of International Oncology, 2023, 50(4): 193-201.
[11]	Xu Meng, Jiang Wei, Zhu Haitao, Cao Xiongfeng. Research progress of cancer-associated fibroblasts in tumor radiotherapy resistance [J]. Journal of International Oncology, 2023, 50(4): 227-230.
[12]	Shi Xaioqi, Wang Hongyan. Research progress on the interaction between gut microbiota and radiation enteritis [J]. Journal of International Oncology, 2023, 50(4): 244-247.
[13]	Zhao Yongrui, Gao Ying, Chen Yidong, Xu Jiankun. Efficacy and safety of linear accelerator-based fractionated stereotactic radiotherapy for small volume brain metastases [J]. Journal of International Oncology, 2023, 50(3): 138-143.
[14]	Huang Huayu, Gong Hongyun, Song Qibin. Influencing factors of pneumonitis in the period of thoracic radiotherapy combined with immunotherapy [J]. Journal of International Oncology, 2023, 50(2): 102-106.
[15]	Cao Xiaohui, Yu Hong, Li Wanhu. Application of CT-based radiomics analysis in predicting and identifying of treatment-associated pneumonitis [J]. Journal of International Oncology, 2023, 50(2): 107-111.